Colorectal adenocarcinoma, cytokeratin immunostaining

Colonic adenocarcinomas1:

 

n

CK7+

CK20+

CK7+/CK20-

CK7-/CK20+

CK7+/CK20+

CK7-/CK20-

primary colon carcinoma1

51

16%

96%

0

80%

16%

4%

primary colon carcinoma (same cases as ovarian metastases below)2

15

47% (7/15)

87% (13/15)

 

 

 

 

primary colon carcinoma3

46

29% (13/46)

87% (40/46)

 

 

 

 

primary colon carcinoma4

75

 

99%(74/75)

 

 

 

 

primary colon carcinoma5

21

 

20

       

total for primary colon carcinoma

112

25% (28/112)

94% (176/187)

 

 

 

 

 

metastatic colon carcinoma1

26

31%

100%

0

69%

31%

0

colon carcinoma metastatic to ovary 2

17

24% (4/17)

76% (13/17)

 

 

 

 

metastatic colon carcinoma4

27

 

96% (27/28)

       

total for metastatic colon carcinoma

43

28% (12/43)

93% (66/71)

 

 

 

 

 

Positivity for CK7 may be more common in anorectal adenocarcinomas, although publications differ:

 

 

CK7+/CK20+

CK7+/CK20-

CK7-/CK20+

CK7-/CK20-

 

Non-neoplastic anorectal mucosa

6/189

3/189

9/189

0/189

Non-neoplastic anal glands

0/1210

12/1210

0/1210

0/1210

Rectal adenoma

1/79

2/79

4/79

0/79

Rectal adenocarcinoma

26/359, 4/3010

0/359, 0/3010

9/359, 26/3010

0/359, 0/3010

Perianal Paget's disease and associated adenocarcinoma

4/411, 3/313

0/411

0/411

0/4|

Anal gland carcinoma

1/712

6/712

0/712

0/712

Colonic adenocarcinoma proximal to rectum

3/119

     
         

Cytokeratin 20 is more often negative in colorectal carcinomas with neuroendocrine differentiation7, in high grade7,8 and right-sided tumours8. Cytokeratin 7 positivity is also more common in high grade tumours8. Cytokeratin 20 expression is reduced in colorectal carcinomas with high levels of microsatellite instability6:

About 15% of sporadic cases of colorectal adenocarcinoma and most cases of hereditary non-polyposis colorectal cancer syndrome are associated with microsatellite instability. There is loss of function of the of the hMLH1 mismatch repair gene. This loss of function is due either to mutation or to aberrant methylation of the promoter region of the gene.

 

 

microsatellite unstable

microsatellite stable

 

mean percentage of cells positive for CK7

7±56

6±56

mean percentage of cells positive for CK20

37±86

84±66

CK7-/CK20+

12/226

17/226

CK7+/CK20+

3/226

3/226

CK7+/CK20-

1/226

0/226

CK7-/CK20-

6/226

2/226

Pancytokeratin cocktail

22/226

22/226

     

 

See also

Differentiation of pulmonary from colonic adenocarcinomas

References

1 Loy TS, Calaluce RD. Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic carcinomas. Am J Clin Pathol 1994;102:764-767.

2 CCAP Wauters et al. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol 1995;26:852-855.

3 JH Lagendijk et al. Tracing the origin of adenocarcinomas with unknown primary using immunhistochemsitry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998;29:491-497.

4 Miettinen M. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial and Merkel cell carcinomas. Mod Pathol 1995;8:384-388.

5 Yatabe, Y., T. Koga, et al. (2004). "CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas." J Pathol 203(2): 645-52.

6 McGregor, D. K., T. T. Wu, et al. (2004). "Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability." Am J Surg Pathol 28(6): 712-8.

7 Kende, A. I., N. J. Carr, et al. (2003). "Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract." Histopathology 42(2): 137-40.

8 Park, S. Y., H. S. Kim, et al. (2002). "Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary." Hum Pathol 33(11): 1078-85.

9 Zhang, P. J., M. Shah, et al. (2003). "Cytokeratin 7 immunoreactivity in rectal adenocarcinomas." Appl Immunohistochem Mol Morphol 11(4): 306-10.

10 Ramalingam, P., W. R. Hart, et al. (2001). "Cytokeratin subset immunostaining in rectal adenocarcinoma and normal anal glands." Arch Pathol Lab Med 125(8): 1074-7.

11 Goldblum, J. R. and W. R. Hart (1998). "Perianal Paget's disease: a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma." Am J Surg Pathol 22(2): 170-9.

12 Hobbs, C. M., M. A. Lowry, et al. (2001). "Anal gland carcinoma." Cancer 92(8): 2045-9.

13 Nowak, M. A., P. Guerriere-Kovach, et al. (1998). "Perianal Paget's disease: distinguishing primary and secondary lesions using immunohistochemical studies including gross cystic disease fluid protein-15 and cytokeratin 20 expression." Arch Pathol Lab Med 122(12): 1077-81.

This page last revised 11.7.2004.